Description

Simple

A cancer chemotherapy medication used to treat several types of cancers.

Clinical

A vinca alkaloid derived from vinblastine used for various types of malignancies, but mainly acute lymphocytic leukemia (ALL).

Overview

Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).

Pharmacology

Indication

For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis

Pharmacodynamic

Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine... Read more

Mechanism of action

Vindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase.

Absorption

Information currently not available.

Protein binding

65-75%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

24 hours.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Regions: Canada
  • Patient Conditions:
      • Name: Demyelinating form of Charcot-Marie-Tooth syndrome
      • Drugbank Id: DBCOND0107603
  • Regions: Canada
  • Patient Conditions:
      • Name: Bacterial Infection
      • Drugbank Id: DBCOND0028997

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vindesine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The risk or severity of bleeding can be increased when (R)-warfarin is combined with Vindesine.
(S)-Warfarin
The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Vindesine.
2-Methoxyethanol
The risk or severity of adverse effects can be increased when Vindesine is combined with 2-Methoxyethanol.
4-hydroxycoumarin
The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Vindesine.
6-Deoxyerythronolide B
The serum concentration of Vindesine can be increased when it is combined with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Vindesine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
The risk or severity of adverse effects can be increased when Vindesine is combined with Abatacept.
Abciximab
The risk or severity of bleeding can be increased when Abciximab is combined with Vindesine.
Abetimus
The risk or severity of adverse effects can be increased when Vindesine is combined with Abetimus.
Acenocoumarol
The risk or severity of bleeding can be increased when Acenocoumarol is combined with Vindesine.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Vindesine.
Acetyldigoxin
Acetyldigoxin may decrease the cardiotoxic activities of Vindesine.
Acetylsalicylic acid
The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Vindesine.
Acteoside
The risk or severity of adverse effects can be increased when Vindesine is combined with Acteoside.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Vindesine.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Vindesine.
Afelimomab
The risk or severity of adverse effects can be increased when Vindesine is combined with Afelimomab.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Vindesine.
Aldosterone
The risk or severity of adverse effects can be increased when Vindesine is combined with Aldosterone.
Aldoxorubicin
The risk or severity of cardiotoxicity can be increased when Vindesine is combined with Aldoxorubicin.